Nkarta (Nkarta) Cash-to-Debt : 2.81 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Nkarta Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Nkarta's cash to debt ratio for the quarter that ended in Dec. 2023 was 2.81.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Nkarta could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Nkarta's Cash-to-Debt or its related term are showing as below:

NKTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.81 Med: 12.09 Max: No Debt
Current: 2.81

During the past 6 years, Nkarta's highest Cash to Debt Ratio was No Debt. The lowest was 2.81. And the median was 12.09.

NKTX's Cash-to-Debt is ranked worse than
63.09% of 1539 companies
in the Biotechnology industry
Industry Median: 6.5 vs NKTX: 2.81

Nkarta Cash-to-Debt Historical Data

The historical data trend for Nkarta's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Nkarta Cash-to-Debt Chart

Nkarta Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

5.07

35.31

19.11

4.25

2.81

Nkarta Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															4.25	3.54	3.10	3.08	2.81

Competitive Comparison of Nkarta's Cash-to-Debt

For the Biotechnology subindustry, Nkarta's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nkarta's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nkarta's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Nkarta's Cash-to-Debt falls into.

Nkarta Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Nkarta's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	248.189	/	(6.069	+	82.27)
	=	2.81

Nkarta's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	248.189	/	(6.069	+	82.27)
	=	2.81

Nkarta (NAS:NKTX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Nkarta Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Nkarta's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Nkarta (Nkarta) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nkarta Inc (NAS:NKTX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

6000 Shoreline Court, Suite 102, South San Francisco, CA, USA, 94080

Website

https://www.nkartatx.com

Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.

Executives

Paul J Hastings	director, officer: See Remarks	61 HARTFORD STREET, SAN FRANCISCO CA 94114
David Shook	officer: Chief Medical Officer	6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Alicia J. Hager	officer: Chief Legal Officer	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Ralph Brandenberger	officer: Sr. VP, Technical Operations	6000 SHORELINE COURT, SUITE 102, SAN FRANCISCO CA 94080
James Trager	officer: Chief Scientific Officer	6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Alyssa Levin	officer: See Remarks	6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Nadir Mahmood	officer: Chief Business Officer	6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Simeon George	director	161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Angela Thedinga	director	C/O ADVERUM BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, MENLO PARK CA 94025
Ra Capital Nexus Fund, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kanya Rajangam	officer: Chief Medical Officer	C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Plc Glaxosmithkline	director, 10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900